Applied DNA Sciences Form 4: Director acquires 22,511 shares at $0

Applied DNA Sciences filed a Form 4 showing a director acquired 22,511 shares of common stock at $0 on 10/17/2025.

Rhea-AI Filing Summary

Applied DNA Sciences filed a Form 4 showing a director acquired 22,511 shares of common stock at $0 on 10/17/2025. Following the transaction, the director beneficially owns 22,512 shares, held directly. The filing notes that 100% of the related restricted stock units vest 90 days from the date of grant.

Insider Trade Summary

Grant/Award: 22,511 shares

Grant/Award 1 txn

Insider SHAMASH YACOV A

Role Director

Type	Security	Shares	Price	Value
Grant/Award	Common Stock	22,511	$0.00	$0.00

Holdings After Transaction: Common Stock — 22,512 shares (Direct)

Footnotes (1)

1. F1. 100% of the restricted stock units vest upon 90 days from the date of grant

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What did APDN disclose in this Form 4?

A director acquired 22,511 shares of common stock at $0 on 10/17/2025.

How many APDN shares does the insider own after the transaction?

The director beneficially owns 22,512 shares following the reported transaction.

What is the relationship of the reporting person to APDN?

The reporting person is a Director of Applied DNA Sciences.

Was the ownership reported as direct or indirect?

The shares are reported as Direct (D) ownership.

What does the filing say about vesting?

It states 100% of the restricted stock units vest 90 days from the date of grant.

What was the transaction price for the acquired shares?

The transaction price reported was $0.

What was the transaction date in APDN’s Form 4?

The transaction date was 10/17/2025.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 10/20/2025 - 05:01 PM Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

SHAMASH YACOV A

(Last) (First) (Middle)

50 HEALTH SCIENCES DRIVE

(Street)

STONY BROOK NY 11790

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
APPLIED DNA SCIENCES INC [ BNBX ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

3. Date of Earliest Transaction (Month/Day/Year)
10/17/2025

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock(1)	10/17/2025		A		22,511	A	$0	22,512	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. 100% of the restricted stock units vest upon 90 days from the date of grant

	/s/ Beth Jantzen, Attorney-in-Fact	10/20/2025
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.